-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, O0zdOM9C8oBR/IfgJOtMP+/KcnjRcvEaf+Btq5/WyhK1AhmISaiR1DOwGdI/f0xh 3tUsBOgz31NeuoZJ3A1GEQ== 0001013762-08-002533.txt : 20081203 0001013762-08-002533.hdr.sgml : 20081203 20081202192413 ACCESSION NUMBER: 0001013762-08-002533 CONFORMED SUBMISSION TYPE: NTN 10K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080831 FILED AS OF DATE: 20081203 DATE AS OF CHANGE: 20081202 EFFECTIVENESS DATE: 20081203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PERCIPIO BIOTHERAPEUTICS, INC. CENTRAL INDEX KEY: 0001046120 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 841432001 STATE OF INCORPORATION: CO FISCAL YEAR END: 1029 FILING VALUES: FORM TYPE: NTN 10K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23559 FILM NUMBER: 081226186 BUSINESS ADDRESS: STREET 1: P. O. BOX 681731 CITY: PARK CITY STATE: UT ZIP: 84068 BUSINESS PHONE: 435-615-6585 MAIL ADDRESS: STREET 1: P. O. BOX 681731 CITY: PARK CITY STATE: UT ZIP: 84068 FORMER COMPANY: FORMER CONFORMED NAME: SUNBURST ACQUISITIONS III INC DATE OF NAME CHANGE: 19970913 NT 10-K 1 form12b25.htm FORM 12-B25 form12b25.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 12b-25
 
NOTIFICATION OF LATE FILING
 
(Check one): [x] Form 10-K [  ] Form 20-F [  ] Form 11-K [  ] Form 10-Q [  ] Form 10-D [  ] Form N-SAR
  [  ] Form N-CSR          

For Period Ended: August 31, 2008

[  ] Transition Report on Form 10-K
[  ] Transition Report on Form 20-F
[  ] Transition Report on Form 11-K
[  ] Transition Report on Form 10-Q
[  ] Transition Report on Form N-SAR
For the Transition Period Ended: _____________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
 
 
PART I — REGISTRANT INFORMATION
 
Percipio Biotherapeutics, Inc.
Full Name of Registrant
 
Former Name if Applicable

10990 Wilshire Blvd., Suite 1410
Address of Principal Executive Office (Street and Number)

Los Angeles, CA 90024
City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
 
  (a) The reason described in reasonable detail in Part III of this form could not beeliminated without unreasonable effort or expense
[X]  (b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subjectquarterly report or transition report on Form 10-Qorsubject distribution report on Form10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has beenattached if applicable
 
 
 
 

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q,10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The registrant is in the process of preparing and reviewing the financial information of the registrant. The process of compiling and disseminating the information required to be included in the Form 10-K for the relevant fiscal year, as well as the completion of the required review of the registrant's financial information, could not be completed without incurring undue hardship and expense. The registrant undertakes the responsibility to file such quarterly report no later than five days after its prescribed due date.

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification
 
 
Richard McKilligan, CFO
  
 (310)
  
696-0333 x125
(Name)
  
(Area Code) 
 
(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s). Yes [X ]No [  ]
 
 
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ?Yes [  ]No [ X]

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

_________Percipio Biotherapeutics, Inc. _______
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
 
       
Date: December 2, 2008    
By:
/s/ Richard McKilligan  
    Name: Richard McKilligan  
    Title: CFO  
       

-----END PRIVACY-ENHANCED MESSAGE-----